查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1413171

PARP 抑制剂药物治疗市场：按药物、适应症、配销通路- 全球预测 2024-2030

PARP Inhibitors Drug Therapy Market by Drug (Niraparib, Olaparib, Rucaparib), Indication (Breast Cancer, Ovarian Cancer, Pancreatic Cancer), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

PARP抑制剂药物治疗市场规模预计2023年为67.3亿美元，2024年达到73.2亿美元，预计2030年将达到124.3亿美元，复合年增长率为9.15%。

全球PARP抑制剂药物治疗市场

主要市场统计
基准年[2023] 67.3亿美元
预测年份 [2024] 73.2亿美元
预测年份 [2030] 124.3亿美元
复合年增长率（%） 9.15%
PARP抑制剂药物治疗市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估PARP抑制剂药物治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对 PARP 抑制剂药物治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-PARP抑制剂药物治疗市场的市场规模和预测是多少？

在 2-PARP 抑制剂药物治疗市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-PARP抑制剂药物治疗市场的技术趋势和法律规范是什么？

4-PARP抑制剂药物治疗市场主要厂商的市场占有率是多少？

5-PARP抑制剂进入药物治疗市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率增加
      • 全球临床试验数量增加
      • 政府增加对 PARP 药物的核准
    • 抑制因素
      • 昂贵的治疗费用
    • 机会
      • 正在进行的研究和开发计划，以引入新的药物疗法
      • 加强癌症治疗方法的政府计划
    • 任务
      • 对药物治疗副作用的担忧
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章 PARP 抑制剂药物治疗市场（依药物划分）

  • 尼拉帕尼
  • 奥拉帕尼
  • 卢卡帕尼
  • 塔拉佐帕尼

第七章 PARP 抑制剂药物治疗市场（按适应症）

  • 乳癌
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第八章 PARP 抑制剂药物治疗市场：按配销通路

  • 医院药房
  • 网路药房
  • 零售药房

第九章 美洲PARP抑制剂药物治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太PARP抑制剂药物治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章：欧洲、中东和非洲的PARP抑制剂药物治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • AbbVie Inc.
    • Artios Pharma Limited
    • AstraZeneca PLC
    • BeiGene, Inc.
    • Bristol-Myers Squibb Company
    • Clovis Oncology
    • GlaxoSmithKline PLC
    • IMPACT Therapeutics
    • Jeil Pharmaceuticals Co. Ltd.
    • Jiangsu Hengrui Pharmaceuticals Company Ltd.
    • Johnson & Johnson Services, Inc.
    • Karyopharm Therapeutics
    • Merck & Co., Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Repare Therapeutics, Inc.
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-AD517FAA718F

[189 Pages Report] The PARP Inhibitors Drug Therapy Market size was estimated at USD 6.73 billion in 2023 and expected to reach USD 7.32 billion in 2024, at a CAGR 9.15% to reach USD 12.43 billion by 2030.

Global PARP Inhibitors Drug Therapy Market

KEY MARKET STATISTICS
Base Year [2023] USD 6.73 billion
Estimated Year [2024] USD 7.32 billion
Forecast Year [2030] USD 12.43 billion
CAGR (%) 9.15%
PARP Inhibitors Drug Therapy Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the PARP Inhibitors Drug Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the PARP Inhibitors Drug Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the PARP Inhibitors Drug Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Artios Pharma Limited, AstraZeneca PLC, BeiGene, Inc., Bristol-Myers Squibb Company, Clovis Oncology, GlaxoSmithKline PLC, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Company Ltd., Johnson & Johnson Services, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Repare Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the PARP Inhibitors Drug Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Niraparib
    • Olaparib
    • Rucaparib
    • Talazoparib
  • Indication
    • Breast Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the PARP Inhibitors Drug Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the PARP Inhibitors Drug Therapy Market?

3. What are the technology trends and regulatory frameworks in the PARP Inhibitors Drug Therapy Market?

4. What is the market share of the leading vendors in the PARP Inhibitors Drug Therapy Market?

5. Which modes and strategic moves are suitable for entering the PARP Inhibitors Drug Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. PARP Inhibitors Drug Therapy Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancers
      • 5.1.1.2. Growing numbers of clinical trials worldwide
      • 5.1.1.3. Elevation in government approvals for PARP drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development projects to introduce novel drug therapies
      • 5.1.3.2. Governmental programs to enhance the cancer treatment therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with side effects of drug therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. PARP Inhibitors Drug Therapy Market, by Drug

  • 6.1. Introduction
  • 6.2. Niraparib
  • 6.3. Olaparib
  • 6.4. Rucaparib
  • 6.5. Talazoparib

7. PARP Inhibitors Drug Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Ovarian Cancer
  • 7.4. Pancreatic Cancer
  • 7.5. Prostate Cancer

8. PARP Inhibitors Drug Therapy Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas PARP Inhibitors Drug Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific PARP Inhibitors Drug Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AbbVie Inc.
    • 13.1.2. Artios Pharma Limited
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. BeiGene, Inc.
    • 13.1.5. Bristol-Myers Squibb Company
    • 13.1.6. Clovis Oncology
    • 13.1.7. GlaxoSmithKline PLC
    • 13.1.8. IMPACT Therapeutics
    • 13.1.9. Jeil Pharmaceuticals Co. Ltd.
    • 13.1.10. Jiangsu Hengrui Pharmaceuticals Company Ltd.
    • 13.1.11. Johnson & Johnson Services, Inc.
    • 13.1.12. Karyopharm Therapeutics
    • 13.1.13. Merck & Co., Inc.
    • 13.1.14. Ono Pharmaceutical Co., Ltd.
    • 13.1.15. Pfizer Inc.
    • 13.1.16. Repare Therapeutics, Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. PARP INHIBITORS DRUG THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PARP INHIBITORS DRUG THERAPY MARKET DYNAMICS
  • FIGURE 7. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 8. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 147. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. PARP INHIBITORS DRUG THERAPY MARKET LICENSE & PRICING